Niva Bupa Health Insurance Company Limited — PPTs, 07-05-2025: Investor Presentation

1. Financial Highlights:

Niva Bupa has announced a board meeting on the financial results for the quarter and half-year. Gross Written Premium (GWP) for FY25 reached ₹7,407 Cr, a 32% YoY increase excluding one-time adjustments. The combined ratio improved to 96%, reflecting better underwriting discipline. I-GAAP Profit after Tax surged 161% YoY to ₹214 Cr, while IFRS PAT grew 91% to ₹203 Cr. Net Worth stood at ₹3,058 Cr, and Assets Under Management rose to ₹8,175 Cr with a yield of 7.4%. Retail health segment GWP grew 26.9% to ₹4,873 Cr, with market share rising to 9.4%. Claims settlement ratio improved to 92.4%, and Net Promoter Score hit 55.

2. Strategic Initiatives & Growth Drivers:

Launch of ‘Rise’ targets the underinsured ‘missing middle’ with flexible payments and unique benefits. Digital adoption is strong—99.9% of new policies are digital; 86% of cashless claims settle within 30 minutes. Investments in tech and analytics enhance real-time underwriting, fraud detection, and customer service. Expansion of Preferred Partner Network hospitals aids claims efficiency and cost control.

3. Business Developments:

Digital and multichannel distribution grew substantially, adding 8,000+ individual agents and expanding broker partnerships. The health and wellness platform attracted over 11.5 million app downloads and 5.1 lakh monthly active users, boosting engagement. Automated claims and policy servicing support operational scalability.

4. Market Position & Competitive Advantage:

Niva Bupa remains among the fastest-growing health insurers in India with a 9.4% retail market share. Accolades as India’s Best Health Insurer and top workplace enhance brand equity. The company’s strong underwriting, claims discipline, and digital capabilities create a clear competitive edge.

5. Investor Implications:

Robust growth, margin improvement, and expense discipline indicate positive growth potential. Tech-driven scalability and customer-focused innovation support sustainable margin expansion. Execution risks include medical cost inflation and competition but are mitigated by strong underwriting and network optimization.